This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the realm of pharma, where the presentation of drug samples is as critical as the information relayed, these bags serve a pivotal role. Far from being just a means of transport, it’s a multi-faceted asset that elevates the art of salesmanship through organization, durability, security, and professional presentation.
After more than two years of pandemic restrictions, many Pharma leaders are itching to meet with their key opinion leaders (KOLs) face-to-face again, believing that’s what most KOLs want. It may come as a surprise that this is not always the case. This is especially true for larger meetings or those covering a large geographical area.
These developments, together with Walgreens’ recent rollout of Health Corners that help patients manage chronic conditions and its October 2022 announcement that it would fully acquire CareCentrix (a platform that coordinates post-acute and home care), underscore Walgreens’ plans to become a leading healthcareprovider.
However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcareproviders (HCPs) as consumers. Technology is upending every aspect of our lives, from retail to transportation. Unfulfilled promise of technology.
Companies must adhere strictly to laws and regulations related to drug safety and maintain stringent quality control procedures throughout every step of production, packaging, transportation, storage, and distribution – all the way through dispensing at the pharmacy level.
Once in the bloodstream, it is transported to its target tissues, inhibiting enzymes (like COX-2) that cause pain and inflammation. A solid grasp of PK and PD is essential for explaining drug benefits and safety to healthcare professionals. Improve communication between healthcareproviders, patients, and pharmaceutical stakeholders.
Kenneth Park, Senior Vice President and General Manager of Life Sciences, moderated a Reuters’ speaker series on the successful applications of precision insights to better understand patient cohorts, hyper-segment markets and healthcareproviders (HCPs), and assess the cost of care.
As healthcareproviders (HCPs) are re-deployed to care for COVID-19 patients, many chronically-ill patients will have less frequent follow-up with their doctors. In fact, these realities are contributing to the virus’s disproportionate impact on minority communities in the United States.
Additionally, this platform is inflation-neutral , allowing teams to gain insight from healthcareproviders, payers, and patients without being affected by external elements. Conclusion The utilization of Impetus InSite Platform® affords various cost-saving benefits.
In 2023, pharmaceutical companies must unlearn the old lessons of commercial engagement, where frequency and face-to-face were key, and focus on the quality of meaningful interaction, where a healthcare professional’s attention is fully engaged and the experience is meaningful to their work.
However, as more firms are called upon to confront social inequity, corruption, tax avoidance, and a lack of security, healthcareproviders and pharma and medical device businesses will need to improve their governance. ESG: Covid-19 and the Ukraine crisis has led to a greater focus on supply chains.
In this blog, we take a close look at health equity in oncology trials specifically, assessing how the lack of diversity and inclusion has impacted cancer patients and the pharma industry’s key initiatives to address it. Clarify launched its real-world evidence on health disparities in 2021.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content